<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362579</url>
  </required_header>
  <id_info>
    <org_study_id>STU00210698</org_study_id>
    <nct_id>NCT04362579</nct_id>
  </id_info>
  <brief_title>Advanced Multi-Modal Wearable Sensing for the Prediction of Pre-Term Labor</brief_title>
  <official_title>Advanced Multi-Modal Wearable Sensing for the Prediction of Pre-Term Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percent agreement of vital signs monitoring between the experimental sensor and standard of&#xD;
      care monitoring&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the Prentice study is to assess and validate EMG performance of the&#xD;
      new home-use sensor with extended battery life in detecting continuous EHG in a range of&#xD;
      uterine contraction intensities, frequencies, and durations compared to gold-standard&#xD;
      FDA-cleared tocodynamometer (GE Corometrics 250cx) in non-stress testing for antepartum&#xD;
      surveillance.&#xD;
&#xD;
      An &quot;at-home&quot; study will validate the developed modifications to the wearable sensors system&#xD;
      that provides a continuous electrohysterography (EHG) along with other additional&#xD;
      physiological parameters (e.g. heart rate, heart rate variability, sleep quality, physical&#xD;
      activity, and continuous blood pressure) for longitudinal monitoring in the home setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Device comparison to standard monitoring</measure>
    <time_frame>2 years</time_frame>
    <description>The primary outcome measure is concordance of FHR tracing assessments from Rogers sensor recordings with those obtained from the current standard of care electronic fetal monitoring systems.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Pregnancy Preterm</condition>
  <arm_group>
    <arm_group_label>Subjects seen in hospital</arm_group_label>
    <description>Subjects will be recruited from Prentice Women's Hospital inpatient antepartum and labor and delivery services, and the outpatient Obstetrics and Gynecology practice, located within Galter tower with the assistance of staff.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Home Study subjects</arm_group_label>
    <description>Subjects will be prescreened by an IRB approved staff and recruited from Prentice Women's Hospital's Department of Obstetrics and Gynecology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>wearable vital signs sensor</intervention_name>
    <description>vital signs monitoring during maternal non-stress testing or in the home setting</description>
    <arm_group_label>Home Study subjects</arm_group_label>
    <arm_group_label>Subjects seen in hospital</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Maternal age &gt;18 years old&#xD;
&#xD;
          -  Pregnant mothers &gt;13 weeks (home study only)&#xD;
&#xD;
          -  Pregnant mothers &gt;26 weeks undergoing nonstress testing or delivering&#xD;
&#xD;
          -  Singleton pregnancy (inpatient or clinic visit patients only)&#xD;
&#xD;
          -  History of preterm labor or premature birth, active smoker, chronic condition (ex: HTN&#xD;
             or DM), or an interval of less than 6 months between the prior pregnancy&#xD;
&#xD;
          -  Singleton pregnancy (home study only)&#xD;
&#xD;
          -  No fetal abnormality or chromosomal abnormality&#xD;
&#xD;
          -  Subjects willing and able to comply with requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Women who refuse to signed the informed consent form&#xD;
&#xD;
          -  Maternal age under 18 years old&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Known major fetal malformation or chromosomal abnormality&#xD;
&#xD;
          -  Medical or obstetric problem that would preclude the use of abdominal electrodes&#xD;
&#xD;
          -  Inability to consent to this study due to medical illness, diminished intellectual&#xD;
             capacity, or language barrier&#xD;
&#xD;
          -  Women using pacemakers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dermatology CTU Dermatology CTU</last_name>
    <phone>312-503-5944</phone>
    <email>DermSensors@northwestern.edu</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Shuai (Steve) Xu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

